ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020
Role of HLA-DP Expression in Graft-Versus-Host Disease After Unrelated Donor Transplantation.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee.Bone marrow transplantation · 2026Guideline
- Ruxolitinib-associated pulmonary alveolar proteinosis successfully managed by switching to belumosudil in chronic graft-versus-host disease.Blood cell therapy · 2026Article
- [Guideline for allogeneic hematopoietic stem cell transplantation in the treatment of transfusion-dependent thalassemia in China (2026)].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Landscapes of HLA Mismatching in Contemporary Unrelated Haematopoietic Cell Transplantation.HLA · 2026Article
- Curative Approach to the Treatment of Beta-Thalassemia and Sickle Cell Disease with Hematopoietic Stem Cell Transplantation.Journal of clinical medicine · 2026Review
- Donor selection, graft engineering, and dosing oh my!Hematology. American Society of Hematology. Education Program · 2025Review
- Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR.Transplantation and cellular therapy · 2025Review
- Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old.Blood · 2025Review
- Decreasing chronic graft-versus-host disease rates in all populations.Blood advances · 2024Article
- A Tool for the Assessment of HLA-DQ Heterodimer Variation in Hematopoietic Cell Transplantation.Transplantation and cellular therapy · 2024Article
- Novel Scoring System for Ranking Hematopoietic Stem Cell Transplantation.Clinical transplantation · 2024Article
- Interplay between donor age and HLA-DP matching in 10/10 HLA-matched unrelated donor HCT.Blood advances · 2024Article
- T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation.Nagoya journal of medical science · 2023Article
- Assessment of HLA-DPB1 genetic variation using an HLA-DP tool and its implications in clinical transplantation.Blood advances · 2023Article
- Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.Nature communications · 2023Article
- Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.Research square · 2023Article
- Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation.Haematologica · 2023Article
- Fine-tuning alloreactivity against HLA-DP to control leukemia with tolerable graft-Haematologica · 2023Article
- Human Leucocyte Antigen System and Selection of Unrelated Hematopoietic Stem Cell Donors: Impact of Patient-Donor (Mis)matching and New Challenges with the Current Technologies.Journal of clinical medicine · 2023Review
- HLA-DPB1 genotype variants predict DP molecule cell surface expression and DP donor specific antibody binding capacity.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 12 institutions in 9 countries.
Funding
Abstract
purposeThe main aim of this study was to evaluate the significance of HLA-DPB1 expression in acute graft-versus-host disease (GVHD) after hematopoietic cell transplantation (HCT) from HLA-A, -B, -C, -DRB1, -DQB1-matched and -mismatched unrelated donors. PATIENTS AND
methodsBetween January 1, 2017, and January 10, 2019, we assessed 19,136 patients who received HCT from an HLA-A, -B, -C, -DRB1, -DQB1-matched or -mismatched unrelated donor performed in Australia, the European Union, Japan, North America, and the United Kingdom between 1988 and 2016. Among transplant recipients with one HLA-DPB1 mismatch, the patient's mismatched HLA-DPB1 allotype was defined as low or high expression. Multivariable regression models were used to assess risks of GVHD associated with high expression relative to low expression HLA-DPB1 mismatches. The effect of increasing numbers of HLA-DPB1 mismatches on clinical outcome was assessed in HLA-mismatched transplant recipients.
resultsIn HLA-A, -B, -C, -DRB1,-DQB1-matched transplant recipients, donor mismatching against one high-expression patient HLA-DPB1 increased moderate (odds ratio [OR], 1.36;
conclusionThe level of expression of patient HLA-DPB1 mismatches informs the risk of GVHD after HLA-A, -B, -C, -DRB1, -DQB1-matched unrelated HCT, and the total number of HLA-DPB1 mismatches informs the risk of GVHD after HLA-mismatched unrelated HCT. Prospective consideration of HLA-DPB1 may help to lower GVHD risks after transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.